-
Junior Chair: Exosomes in valvular calcification
Matthieu Lecuyer recently joined our laboratory on a Junior Professor Chair position at Rouen Normandy University to support research and formation within the Cribier Valve Institute. He will work at EnVI laboratory to investigate the roles of Extra-Cellular Vesicles/Exosomes in valvular calcification, in a project entitled: "Development of innovative treatments for the management of cardiac valvular diseases".
- Valvular heart diseases are common and increasing in prevalence due to population aging, with an incidence comparable to that of Alzheimer’s disease. Their pathophysiology remains poorly understood, and no treatment currently exists to halt or slow their progression. Building on ten years of collaborative experience (FHU/RHU), the Alain Cribier Institute aims to bring together all the key players in the field of cardiac valves on a single site. Matthieu will be responsible for coordinating preclinical and translational research in the field of therapeutic innovation for the management of valvular heart diseases—particularly calcified aortic stenosis—aligned with Axis 2 of INSERM Unit 1096, in collaboration with the Cardiology and Cardiothoracic Surgery Departments of the Rouen University Hospital. His responsibilities include:
- Managing the isolation and study of valvular cells
- Organotypic culture of murine, porcine, or human explanted valves
- In vivo studies in murine models of aortic stenosis, particularly in contexts of kidney failure induced by nephrectomy or metabolic disorders
- Establishing methodologies for studying bioprosthetic valve degeneration in rodents (subcutaneous implantation)
- Setting up a large animal model (sheep or pig) for in vivo investigation of the mechanisms and surgical or pharmacological treatments of aortic stenosis
- Leading and conducting biological studies in support of clinical trials and cohort studies carried out within the Institute.
- Research Background and Expertise

- Matthieu has a background as a polyvalent researcher with extensive experience in Neurosciences field, gained in France, USA and Switzerland in various sectors, including academia and the private sector (biotech startup).
- In 2017, he obtained his PhD in molecular biology /neurosciences at Inserm UMR1245 Rouen University Normandy, studying the 'Impact of magnesium sulfate and fetal alcohol exposure on neurovascular interactions during development', under guidance by Dr. Bruno Gonzalez. During his thesis, Matthieu contributed to several articles (e.g. PMID: 38269113, 30340542, 28805973,
- 28587682, 30671527, 28922852) as well as 2 patents: i) The first biomarker of ‘brain alcohol effect’, which may help in early diagnosis, and ii) Validation of a Therapeutic Target for fetal alcohol exposure.
- Then, he moved to the US in 2018 for a postdoc at UCSF (University of California San Francisco), where he participated in two major projects: i) Neonatal stroke and Extra-Cellular Vesicles/Exosome modulation, and 2) Effects of Omega-3 on neonatal stroke. This experience led to several publications (e.g. PMID: 34153465, 34235636, 34674145, 32269105 ), and establishment of Matthieu as an expert on extra-cellular vesicles.
- Subsequently, Matthieu moved to Switzerland to join a start-up company (Mosaic NeuroSciences). Here, Matthieu spearheaded the establishment and management of a new research laboratory, and he established a new research direction by investigating the potential of genetic decoration of neural exosomes with proprietary biopolymer to extend the exosome's half-life in plasma.
-
New article published in EMBO Mol Med
In a new article published in EMBO Mol Med we demonstrate that cardiac lymphatic clearance of fluids and immune cells may be reduced in heart failure. In a model of pressure-overload heart failure, we show that myocardial inflammation alters lymphatic gene expression, which could limit fluid drainage, while lymphatic immune attraction profiles remain intact.
-
Myocardial inflammation reduces the expression of key lymphatic barrier genes (Cldn5 and Tjp1), thereby impairing lymphatic function.
-
Newly formed lymphatic capillaries lack valves, which further compromises directional fluid transport from the heart to the draining lymph nodes.
-
Lymphatic endothelial cells upregulate immune-modulatory genes (Ccl21 and Lyve1), which may partially compensate for the reduced flow by attracting more immune cells to the lymphatics.
-
Restoring lymphatic barrier integrity and valve formation are potential new therapeutic targets to improve myocardial fluid clearance, accelerate resolution of inflammation, and slow heart failure progression.

-
-
Epigenetic check-point regulates polarization of monocytes post-MI
Myocardial infarction (MI) triggers a wound healing response that involves rapid recruitment of immune cells, notably myeloid cells, to the heart. This innate immune response is required for efficient healing, and alteration of its kinetics may contribute to poor infarct remodeling driving heart failure development. In the latest issue of Nature Communications, the team led by Dr. Fraineau described for the first time the role of an epigenetic switch in regulating the kinetics and profiles of the innate immune response post-MI. Specifically, they uncovered that an epigenetic transcriptional repressive enzyme, named EZH2, serves as an epigenetic check-point during polarization of monocytes toward an immunomodulatory pro-regenerative macrophage phenotype. Using an epigenetic pharmacological inhibitor of EZH2, this check-point can be suppressed, thus enhancing the transcriptomic program resulting in generation of more immunomodulatory macrophages. This led to an acceleration of the innate immune response after MI, resulting in reduced deleterious infarct scar remodeling, and prevention of post-MI aggravation of cardiac dysfunction. Altogether, Fraineau et al. identified an original epigenetic mechanism governing macrophage polarization toward either proinflammatory or immunomodulatory phenotypes, thus revealing epigenetic mechanisms as a novel therapeutic target to improve inflammatory kinetics post-MI to prevent heart failure development.
See further: open access article or video presentation by Dr Fraineau
-
Inserm U1096 in the news
Previous media articles on our research:
- Memory services for Pr Alain Cribier Décès du Professeur Alain Cribier - Université de Rouen Normandie (univ-rouen.fr), Hommage au Professeur Alain Cribier (chu-rouen.fr)
- Highlight on chronic kidney disease by lab member Pr D Guerrot
- Highlight of our preclinical research in The Conversation
- Projet FHU CARNAVAL
- FASEB BIOART 2020
- RHU STOP-AS (@RHU_STOPAS) | FDNitter
- Projet RHU STOP-AS sélectioné
- Un reseau invisible au secours du coeur
- Prix Jean-Paul Binet
- Ma thèse en 180 secondes
- Prix "Don de soi -don de vie"
- Réseau ERA-CVD LYMIT-DIS
- Réseau FHU REMOD-VHF
- Helene Eltchaninoff, membre de la Fédération Hospitalo-Universitaire - Portail vidéo de l'Université de Rouen Normandie (univ-rouen.fr)
Inserm U1096 - Laboratory EnVI
Research performed in Inserm U1096 Unit in Rouen, concerns evaluation of the mechanisms behind and novel treatments of cardiovascular diseases, focusing on vascular protection and improvement of cardiac contractile function. This research is transversal, and performed both in experimental models and in human.
EnVI lab (@INSERMU1096) / Twitter





